Gregory Goldgof, MD, PhD

Myelodysplastic syndromes (MDS) are blood cancers that begin in the bone marrow, where blood cells are made. Over time, MDS can progress to acute myeloid leukemia, an aggressive and often life-threatening cancer. Diagnosing MDS and predicting how it will behave can be challenging because doctors must look for subtle abnormalities in blood and bone marrow cells under a microscope. Dr. Goldgof is developing artificial intelligence that can analyze these cells automatically and combine what it sees with a patient's genetic and clinical information. The goal is to help doctors detect disease earlier, better predict outcomes, and select the most effective treatment for each patient.